ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2210

Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality

Rebecca Brooks1, Sara Achenbach2, Vanessa Kronzer1, Elena Myasoedova1, Cynthia Crowson1 and John Davis1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Rochester, MN

Meeting: ACR Convergence 2024

Keywords: Anti-CCP, Mortality, radiography, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Both RF and anti-CCP are associated with erosive disease, increased disease activity, and adverse outcomes in RA. However, there have been limited studies investigating how RF and anti-CCP interact to influence outcomes. We aimed to compare the radiographic erosions, disease flares, and mortality in four cohorts of patients defined by the presence or absence of RF and anti-CCP.

Methods: This retrospective cohort study includes residents of a geographically defined area with incident RA between 2003 and 2019. The index date was defined as the date of fulfillment of either the 1987 ACR or 2010 ACR/EULAR classification criteria. Patient characteristics were abstracted from medical records. RF and anti-CCP seropositivity status were determined prior to the index date or within one year following to determine the impact of baseline seropositivity on prognosis. Comparison of baseline characteristics between cohorts was performed using chi-square and rank-sum tests. Cox models adjusted for age, sex, smoking status, comorbidities, and calendar year were used to examine the association between seropositivity status and all-cause mortality.

Results: The study included a total of 1,080 patients with RA, with a mean age of 56 years, 69% female and 36% being seronegative, 38% dual seropositive, 13% seropositive for only anti-CCP, and 12% seropositive for RF only. At baseline, 70% of the cohort only seropositive for anti-CCP had been prescribed methotrexate and only 56% of the cohort seropositive for RF only had a prescription for methotrexate. At baseline, 28% of the dual seropositive cohort had radiographic evidence of erosions. Surprisingly, 22% of the cohort seronegative for RA had evidence of erosions along with 22% of the cohort with only RF seropositivity. In contrast, the cohort only seropositive for anti-CCP had 13% of patients with erosions. 96% of the patients in the dual seropositive cohort had at least one visit within the first year of diagnosis for an RA flare. The cohort with the highest percentage of severe extra-articular manifestations was seropositive for RF only (Table 1). Patients with only RF seropositivity had over two times higher mortality compared to patients with seronegative RA (aHR 2.32 [95% CI 1.52-3.54]). Although patients with dual seropositivity had an increase in mortality, it was lower with only a 65% increase (aHR 1.65 [95% CI 1.16-2.34]) and patients with only anti-CCP seropositivity had only a 27% increase in mortality (aHR 1.27 [95% CI 0.75-2.15]) (Table 2).

Conclusion: Among patients with RA, almost a quarter of the seronegative, only RF seropositive, and dual seropositive cohorts had radiographic evidence of erosions at baseline, and the majority of all cohorts had at least one visit for a RA flare within the first year. Interestingly, the cohort that was seropositive for RF only had the highest mortality. This could partially be explained due to the delay in treatment with DMARDs such as methotrexate. Our study suggests that seropositivity for RF is a driver of increased mortality and that it does not interact with anti-CCP to further increase mortality. To optimize the long-term outcomes in RA, increased attention to RF seropositivity at baseline may be warranted.

Supporting image 1

Table 1. Baseline characteristics of RA Patients as determined by RF and Anti-CCP seropositivity

Supporting image 2

Table 2. Associations between seropositivity and mortality


Disclosures: R. Brooks: None; S. Achenbach: None; V. Kronzer: None; E. Myasoedova: None; C. Crowson: None; J. Davis: Girihlet, 10, NLC Health Ventures, 10, Pfizer, 5, Remission Medical, 10.

To cite this abstract in AMA style:

Brooks R, Achenbach S, Kronzer V, Myasoedova E, Crowson C, Davis J. Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comparison-of-dual-rf-and-anti-ccp-seropositive-single-seropositive-and-seronegative-ra-on-radiographic-changes-flares-and-mortality/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-dual-rf-and-anti-ccp-seropositive-single-seropositive-and-seronegative-ra-on-radiographic-changes-flares-and-mortality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology